Rabbit Recombinant Monoclonal SUPT16H antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.31% Sodium citrate, 0.175% Sodium chloride, 0.05% BSA, 0.0172% EDTA
ICC/IF | IP | Flow Cyt | WB | IHC-P | |
---|---|---|---|---|---|
Human | Not recommended | Not recommended | Not recommended | Tested | Not recommended |
Mouse | Not recommended | Not recommended | Not recommended | Predicted | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 - 1/10000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse | Dilution info - | Notes - |
Select an associated product type
Component of the FACT complex, a general chromatin factor that acts to reorganize nucleosomes. The FACT complex is involved in multiple processes that require DNA as a template such as mRNA elongation, DNA replication and DNA repair. During transcription elongation the FACT complex acts as a histone chaperone that both destabilizes and restores nucleosomal structure. It facilitates the passage of RNA polymerase II and transcription by promoting the dissociation of one histone H2A-H2B dimer from the nucleosome, then subsequently promotes the reestablishment of the nucleosome following the passage of RNA polymerase II. The FACT complex is probably also involved in phosphorylation of 'Ser-392' of p53/TP53 via its association with CK2 (casein kinase II).
FACT140, FACTP140, SUPT16H, FACT complex subunit SPT16, Chromatin-specific transcription elongation factor 140 kDa subunit, FACT 140 kDa subunit, FACTp140, Facilitates chromatin transcription complex subunit SPT16, hSPT16
Rabbit Recombinant Monoclonal SUPT16H antibody. Suitable for WB and reacts with Human samples. Cited in 1 publication.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.31% Sodium citrate, 0.175% Sodium chloride, 0.05% BSA, 0.0172% EDTA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
SUPT16H also known as FACT80 is a protein that plays an important mechanical role in chromatin remodeling. It has a molecular mass of approximately 142 kDa. This protein becomes substantially expressed in actively dividing cells particularly in tissues with high rates of cell proliferation such as the bone marrow and epithelial layers. SUPT16H along with SSRP1 forms a heterodimeric structure that functions as the Facilitates Chromatin Transcription (FACT) complex which modulates nucleosome organization during transcription elongation.
The SUPT16H protein operates by working within the FACT complex to unravel nucleosomes allowing RNA polymerase II to move along DNA more efficiently by transiently modifying chromatin structure. This function is essential during the transcriptional elongation process making it pivotal in gene expression regulation. The protein as part of the FACT complex participates in chromatin destabilization and reassembly proving important in maintaining chromatin integrity during cell cycle progression and other cellular stress responses.
SUPT16H plays a role in the transcriptional regulation pathway. It is strongly linked to pathways like the p53 signaling pathway which responds to DNA damage and maintains genomic stability. Within these pathways SUPT16H interacts with proteins such as RNA polymerase II highlighting its role in transcriptional regulation. In direct relation to this function SUPT16H also connects with p53-related proteins modulating their transcriptional activity in response to cellular changes.
The SUPT16H protein has demonstrated involvement in various cancer types due to its role in gene expression regulation. Aberrations in its function can lead to dysregulated transcription contributing to oncogenic transformations. Furthermore SUPT16H ties into neurodegenerative disorders such as Alzheimer's disease where altered chromatin dynamics may impact neuronal survival. In these contexts SUPT16H associates with cancer-related proteins and those involved in neuronal signaling pathways highlighting its importance in disease pathogenesis.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-SUPT16H antibody [EPR3685] (ab108960) at 1/1000 dilution
Lane 1: HeLa cell lysate at 10 µg
Lane 2: Jurkat cell lysate at 10 µg
Lane 3: A549 cell lysate at 10 µg
Predicted band size: 120 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com